Lantern Pharma Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum of Drug-Resistant Lung Cancers in the Journal Oncotarget

- Preclinical evidence supports the development of LP-184 in non-small cell lung cancers (NSCLC) for patients ineligible for targeted therapy - LP-184 shows nanomolar potency in in vitro lung cancer models that are resistant to other cancer drugs

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here